Abstract
Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 675-688 |
Number of pages | 14 |
Journal | Expert Opinion on Therapeutic Targets |
Volume | 13 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2009 |
Keywords
- Cyclooxygenase-2
- Eicosanoids
- Non-small-cell lung cancer
- Prostaglandin E
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry